Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vizol S DIGI EYE in moderate to severe dry eye disease
NCT07050446Phase 3Completed
- Sponsor
- JGL Group
- Start
- Mar 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 3 trial of Vizol S DIGI EYE in dry eye disease (DED), sponsored by JGL Group. Started Mar 2024; status: completed.
02
Drugs
Vizol S DIGI EYE
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07050446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050446.